With help from No­var­tis and Sanofi, Neu­roVia heads to the clin­ic armed with a $14M round

The cor­po­rate ven­ture arms of No­var­tis and Sanofi have joined hands to back a $14 mil­lion Se­ries A for a vir­tu­al start­up called Neu­roVia, which has a new drug head­ed for the clin­ic de­signed to tack­le rare cas­es of X-linked adrenoleukody­s­tro­phy, or X-ALD.

No­var­tis Ven­ture’s Gio­van­ni Fer­rara helped found the com­pa­ny, ini­tial­ly adding a con­sid­er­able amount to seed the com­pa­ny in 2015 and sup­port the three full timers and pla­toon of con­sul­tants brought in to set things up. No­var­tis Ven­ture Fund and Sanofi-Gen­zyme BioVen­tures co-led the $14 mil­lion Se­ries A that’s come to­geth­er, with con­tri­bu­tions from Bio­Med Ven­tures and En­so Ven­tures.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.